Skip to main content

Table 1 Clinicopathological data of analyzed cases

From: Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy

   Number of cases Total % Valid %
Age 40 ≥ 29 24.2 24.2
40 < 91 75.8 75.8
cT T1 19 15.8 15.8
T2 73 60.8 60.8
T3 15 12.5 12.5
T4 13 10.8 10.8
pT pT0 20 16.7 18.7
pT1 40 33.3 37.4
pT2 34 28.3 31.8
pT3 9 7.5 8.4
pT4 4 3.3 3.7
Unknown 13 10.8  
cN N0 46 38.3 40.4
N1 55 45.8 48.3
N2 9 7.5 7.9
N3 4 3.3 3.5
Nx 6 5.0  
pN pN0 51 42.5 48.1
pN1 36 30 33.9
pN2 13 10.8 12.3
pN3 6 5 5.7
Nx 14 11.7  
Grade 1 1 0.8 0.9
2 46 38.3 41.8
3 63 52.5 57.3
Unknown 10 8.3  
ER status Positive 80 66.7 66.7
Negative 40 33.3 33.3
PgR status 20% > 8 6.7 6.7
20% ≤ 49 40.8 41.2
Negative 62 51.7 52.1
Unknown 1 0.8  
HER2 status Positive 41 34.2 34.2
Negative 79 65.8 65.8
Histological type Lobular 6 5.0 5.1
IBC NOS 112 93.3 94.9
Other/Unknown 2 1.7  
Molecular subtype Luminal A 15 12.5 12.5
Luminal B/HER2- 38 31.7 31.7
Luminal B/HER2+ 27 22.5 22.5
HER2+ 14 11.7 11.7
Triple-negative 26 21.7 21.7
Response Complete 23 19.2 19.2
Partial 73 60.8 60.8
Non-responder 24 20.0 20.0
Antracyclines Yes 88 73.3 73.3
No 32 26.7 26.7
Taxanes Yes 99 82.5 82.5
No 21 17.5 17.5
Platinum Yes 31 25.83 25.83
No 89 74.16 74.16
Trastuzumab Yes 12 10.0 10.0
No 108 90.0 90.0